Vycor Viewsite Brain Access System (VBAS): Class 1 Recall - Unidentified Fiber Found on Device

AUDIENCE: Neurology, Surgery, Risk Managers
ISSUE: Vycor Medical recalled its VBAS because an unidentified black fiber was found on the device. This product may cause serious adverse health consequences, including death. 
BACKGROUND: The Vycor Medical Viewsite Brain Access System serves as a self-retaining retractor system for brain tissue and provides access to allow the surgeon to see the surgical site during brain and spinal procedures. 
RECOMMENDATION: Vycor Medical called their customers requesting that they place products of Model # TC171105, Lot # VM83450 into quarantine until further notice. Vycor Medical asked customers holding the affected lot numbers to call the company immediately.  Customers in immediate need of the product should advise the Vycor customer service team who can assist in providing an alternative product.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

• Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
• Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, including links to the Recall notice, at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm337475.htm

Related articles

• Zolpidem2013
• Mobius Theraputics??? Issues a Voluntary Recall of Mitosol
• Dangerous Supplement Now Sold as 'WOW'
• The Aspartame Epidemic
• Freedom Trading Issues a Voluntary Nationwide Recall of Super Power...
• Some Sleep Drugs Can Impair Driving
• D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
• Guns v Vioxx: Murder is ok if you are big pharma
• FDA's Hazard Analysis and Risk-Based Preventive Controls for Human Food and Current Good Manufacturing Practice (Part 2 of 3)
• Mobius Therapeutics, LLC Issues a Voluntary Recall of Mitosol(R) (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use